Transformation continued with one-time costs and staff reductions, while R&D advanced key AmorphOX-based projects. Financials showed negative cash flow and higher OpEx due to settlements and legal fees, with SEK 233 million cash remaining. DOJ settlement and partnering efforts remain key near-term priorities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.